Le Lézard
Classified in: Ebola virus, Health, Business
Subjects: ERN, ACC

Essity: Year-end Report 2017


STOCKHOLM, Jan. 25, 2018 /PRNewswire/ --

JANUARY 1 ? DECEMBER 31, 2017
(compared with the corresponding period a year ago)

[1]Indicative earnings per share on the assumption that the number of issued shares in Essity as of December 31, 2016 corresponded to the number of issued shares in Essity on December 31, 2017 (702.3 million).

SUMMARY OF THE FULL YEAR AND FOURTH QUARTER OF 2017

The Group's net sales for 2017 increased 8.0% compared with the preceding year. Organic sales increased 1.2%. The Group's adjusted EBITA for full-year 2017 rose 12%. Excluding currency translation effects and the acquisition of BSN medical, adjusted EBITA increased 1%. The Group's adjusted EBITA margin rose 0.5 percentage points to 12.3%. The adjusted return on capital employed was 14.9%.

The Board of Directors proposes a dividend of SEK 5.75 per share.

The Group's net sales for the fourth quarter of 2017 increased 7.1% compared with the corresponding period a year ago. Organic sales increased 1.8%, of which volume accounted for 0.8% and price/mix for 1.0%. In emerging markets, which represented 35% of net sales, organic sales rose 5.9%, while in mature markets organic sales declined 0.3%. Organic sales were negatively impacted by lower market growth due to such factors as price pressure and as a consequence of Essity's decision to discontinue certain underperforming market positions and contracts as part of the company's focus on profitable growth for increased value creation. During the quarter, five innovations were launched that strengthened Essity's customer and consumer offering.

The Group's adjusted EBITA in the fourth quarter of 2017 increased 13% compared with the corresponding period a year ago. Excluding currency translation effects and the acquisition of BSN medical, adjusted EBITA rose 3%. The increase was mainly the result of a better price/mix, higher volumes, cost savings and other measures to improve profitability. Higher raw material costs had a negative impact of SEK 713m. The Group's adjusted EBITA margin increased 0.7 percentage points to 12.6%. The adjusted return on capital employed was 14.4%.

For the fourth quarter of 2017, the acquired company BSN medical's organic sales rose by 2.4%. The adjusted EBITA margin for the acquired company was 18.4% and was negatively impacted by approximately 0.5 percentage points as a result of integration costs.

FUTURE REPORTS
Essity's 2017 Annual and Sustainability Report is scheduled for publication during the week beginning March 19, 2018.

In 2018, interim reports will be published on April 27, July 19 and October 26.

ANNUAL GENERAL MEETING
The Annual General Meeting for Essity will be held on April 12, 2018 at 15:00 CET at the Stockholm Waterfront Congress Centre in Stockholm, Sweden.

INVITATION TO PRESS CONFERENCE ON YEAR-END REPORT 2017
Media and analysts are invited to a press conference, where this year-end report will be presented by Magnus Groth, President and CEO.

Time: 13:00 CET, Thursday, January 25, 2018
Location: Essity's headquarters, Waterfront Building, Klarabergsviadukten 63, Stockholm, Sweden

The presentation will be webcast at www.essity.com. To participate, call: +44 (0) 145-254-10-03, +1 646-741-21-20 or +46-8-566-194-45. Specify "Essity" or conference ID no. 8239169.

Essity Aktiebolag (publ)

Magnus Groth
President and CEO

For further information, please contact:
Fredrik Rystedt
CFO and Executive Vice President
+46-8-788-51-31

Johan Karlsson
Vice President Investor Relations
Group Function Communications
+46-8-788-51-30

Joséphine Edwall-Björklund
Senior Vice President
Group Function Communications
+46-8-788-52-34

Media Relations
Group Function Communications
+46-8-788-52-20

NB:

This information is such information that Essity Aktiebolag (publ) is obligated to make public pursuant to the EU Market Abuse Regulation. This report has been prepared in both Swedish and English versions. In case of variations in the content between the two versions, the Swedish version shall govern. The information was submitted for publication, through the agency of the contact person set out below, at 12:00 noon CET on January 25, 2018. This interim report has not been reviewed by the company's auditors.

Karl Stoltz
Media Relations Manager
+46-8-788-51-55

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/essity/r/year-end-report-2017,c2438166

The following files are available for download:

http://mb.cision.com/Main/15798/2438166/782134.pdf

The full report (PDF)

 

 

SOURCE Essity


These press releases may also interest you

at 07:28
BioArctic AB (publ) today announced that BioArctic AB and Eisai Co., Ltd., have entered into a research evaluation agreement regarding BAN2802, a potential new treatment combining BioArctic's proprietary BrainTransportertm technology with an...

at 07:00
LifeLabs workers from Orillia, Barrie, Collingwood, and Wasaga Beach will rally with community members and allies ahead of their imminent strike deadline. They stand firm in their demands for a fair contract that puts patients and workers before...

19 avr 2024
Remedium Healthcare Products is proud to announce the launch of NuVeria Labs' revolutionary Sacral Silicone Dressing, now available for purchase on Amazon, bringing advanced wound care solutions directly to consumers' doorsteps. Designed to address...

19 avr 2024
Getting specialty medications into...

19 avr 2024
Arthrex, a global leader in minimally invasive surgical technology, has once again taken home prestigious medals for product innovation at the 37th annual Edison Awards. "This product, along with our other innovations,...

19 avr 2024
Aligned with the trend of immersive water therapy in 2024, Baros Maldives' Serenity Spa stands out as an oasis of indulgent spa and beauty rituals, boasting a 50-year legacy of luxury. Nestled within a tranquil sanctuary amidst the lush Maldivian...



News published on and distributed by: